Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.42%
1,101.74
-4.62
-0.42%
—1,106.361,105.681,109.291,096.52——
SIXC
Communications
SIXC
Communications
SIXC
+0.43%
612.89
+2.60
+0.43%
—610.29610.29616.60610.29——
SIXE
Energy
SIXE
Energy
SIXE
+0.73%
1,220.03
+8.81
+0.73%
—1,211.221,211.011,221.411,208.50——
SIXI
Industrials
SIXI
Industrials
SIXI
+0.41%
1,757.83
+7.48
+0.41%
—1,750.711,753.101,762.131,743.30——
SIXM
Financials
SIXM
Financials
SIXM
+0.59%
631.86
+3.69
+0.59%
—628.17629.38634.09629.38——
SIXR
Staples
SIXR
Staples
SIXR
+0.32%
857.31
+2.74
+0.32%
—854.57855.71860.09855.45——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0.57%
215.63
-1.24
-0.57%
—216.87216.87217.79215.51——
SIXT
Technology
SIXT
Technology
SIXT
+1.40%
3,611.87
+49.93
+1.40%
—3,561.943,571.443,628.583,562.15——
SIXU
Utilities
SIXU
Utilities
SIXU
+0.14%
904.60
+1.29
+0.14%
—903.31903.26906.56901.18——
SIXV
Health care
SIXV
Health care
SIXV
-0.18%
1,478.83
-2.71
-0.18%
—1,481.541,482.481,488.461,474.18——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0.23%
2,405.42
+5.47
+0.23%
—2,399.952,404.452,418.812,398.09——
Q4 2026 earnings • released • EPS miss -46.93% • Revenue miss -7.39%
See results
RDY:NYSE
Dr Reddy's Laboratories Ltd
$13.49
+3.93%
(+0.51) 1D
May 14, 2:23:20 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RDY...
Open
$13.40
High
$13.64
Low
$13.34
Mkt. cap
11.45B
Avg. vol.
2.93M
Volume
1.94M
Dividend
0.68%
Quarterly dividend
$0.02
Ex dividend date
Jul 10, 2026
P/E ratio
25.13
52-wk high
$16.17
52-wk low
$12.18
EPS
$0.54
Beta
0.29
Shares outstanding
834.62M
No. of employees
28K
News stories
From sources across the web
Profile
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology. Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe. By 2007, Dr. Wikipedia
About Dr Reddy's Laboratories Ltd
CEOErez Israeli
Employees27.8K
Founded1984
HeadquartersHyderabad, Andhra Pradesh, India
SectorPharmaceutical industry
Websitedrreddys.com
Last report
May 12, 2026
Fiscal Period
Q4 2026
EPS / Est. (INR)
₹5.74 / ₹10.82
-46.93%miss
Revenue / Est. (INR)
75.16B / 81.16B
-7.39%miss
Fiscal Q4 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
85.45B
88.05B
87.27B
75.16B
Cost of goods sold
36.82B
39.91B
40.46B
41.47B
Cost of revenue
36.82B
39.91B
40.46B
41.47B
Research and development expenses
6.24B
6.20B
6.15B
5.46B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
25.65B
26.44B
26.92B
27.76B
Operating expense
31.11B
31.90B
32.48B
29.78B
Total operating expenses
67.94B
71.81B
72.94B
71.25B
Operating income
17.52B
16.24B
14.33B
3.91B
Other non operating income
-
1.28B
570.00M
1.68B
EBT including unusual items
19.05B
18.35B
15.43B
1.99B
EBT excluding unusual items
18.36B
17.81B
15.52B
4.58B
Income tax expense
4.95B
4.08B
3.53B
-214.00M
Effective tax rate
25.99%
22.24%
22.90%
-10.75%
Other operating expenses
-779.00M
-740.00M
-591.00M
-3.44B
Net income
14.18B
14.37B
12.10B
2.20B
Net profit margin
16.59%
16.32%
13.86%
2.93%
Earnings per share
17.02
17.87
14.77
5.74
Interest and investment income
1.13B
912.00M
796.00M
-
Interest expense
-830.00M
-907.00M
-944.00M
-1.06B
Net interest expenses
298.00M
5.00M
-148.00M
-1.06B
Depreciation and amortization charges
-
-
-
-
EBITDA
22.28B
21.29B
19.54B
9.49B
Gain or loss from assets sale
40.00M
-308.00M
-179.00M
-2.10B
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer